Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Leong
Observed name:
S. Leong
Institution:
University College London Hospitals NHS Foundation Trust
Observed institutions:
University College Hospital,
University College London Hospitals NHS Foundation Trust,
National Institute for Health and Care Research,
UCL Biomedical Research Centre,
Addenbrooke's Hospital,
University College London
show all 6
ORCID:
0000-0002-7794-7732
Observed ORCID:
0000-0002-7794-7732
OpenAlex ID:
A5038286014
RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
2022
·
Carmelo Carlo-Stella
, Rita Mazza
, et al.
·
Blood
·
99
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
2024
·
Jad Othman
, Ho Pui Jeff Lam
, et al.
·
Blood Neoplasia
·
57
Antibody drug conjugates for the treatment of multiple myeloma
2022
·
Sarah Leong
, Ho Pui Jeff Lam
, et al.
·
American Journal of Hematology
·
31
PDF
S180: Rg6234, a Novel Gprc5d T-cell Engaging Bispecific Antibody, Induces Rapid Responses in Patients With Relapsed/refractory Multiple Myeloma: Preliminary Results From a First-in-human Trial
2022
·
C. Hasselbalch Riley
, M. Hutchings
, et al.
·
HemaSphere
·
24
CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy
2020
·
Sarah Leong
, Sarah Inglott
, et al.
·
Blood Advances
·
24
Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
2023
·
William Townsend
, Sarah Leong
, et al.
·
Blood
·
18
Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
2022
·
Iryna Dekhtiarenko
, Iva Lelios
, et al.
·
Blood
·
9
First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
2022
·
William Townsend
, Sarah Leong
, et al.
·
Blood
·
9
Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme
2022
·
Henry Wood
, Christianne Bourlon
, et al.
·
Blood
·
6
Encouraging long-term efficacy and safety from first-in-human phase 1 study of time-limited NVG-111 in relapsed/refractory CLL and MCL
2025
·
William Townsend
, Sarah Leong
, et al.
·
Blood
·
2
PDF
S173: T-cell Activation and Myeloma Cell Killing Confirm the Mode of Action of Rg6234, a Novel Gprc5d T-cell Engaging Bispecific Antibody, in Patients With Relapsed/refractory Multiple Myeloma
2022
·
I. Dekhtiarenko
, I. Lelios
, et al.
·
HemaSphere
·
2
Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)
2019
·
William Townsend
, Sarah Leong
, et al.
·
British Journal of Haematology
·
2
PDF
P547: Characteristics and Outcomes of Patients With Acute Myeloid Leukaemia Treated With Venetoclax Combination Therapy: Real-world Experience in Both Frontline and Relapsed/refractory Settings
2022
·
H. P. J. Lam
, S. Leong
, et al.
·
HemaSphere
·
1
Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience
2026
·
Wei Yee Chan
, Hannah Al‐Yousuf
, et al.
·
British Journal of Haematology
Show more works
View as search
Works count:
14
Citation count:
284
H-index:
8
I10-index:
6
Year
Topic
Type